Datum | Källa | Rubrik | Typ | Alternativ |
---|---|---|---|---|
2024-04-23 | Vivesto | Vivesto publicerar årsredovisning för 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-04-23 | Vivesto | Notice of Annual General Meeting in Vivesto AB | Pressreleaser | Ladda ner | Visa Stäng |
Pressreleaser |
Notice of Annual General Meeting in Vivesto ABThe shareholders of Vivesto AB, Reg. No. 556332-6676 (”Vivesto” or the ”company”), are hereby summoned to the Annual General Meeting to be held at 10:00 a.m. CEST on Thursday, 23 May 2024, at Gustav III:s Boulevard 42, ground floor, SE-169 73 Solna, Sweden. The Board of Directors has, pursuant to the company’s Articles of Association, resolved that the shareholders shall have the opportunity to exercise their voting rights by postal voting prior to the Annual General Meeting. Shareholders may thus choose to attend the meeting in person, by proxy or by postal voting. Right to attend • by mail: Vivesto AB, Box 3061, SE-169 03 Solna, Sweden, or The notice of participation should state name, personal identification number or corporate registration number, postal address, telephone number, shareholding and, where applicable, information about any proxy or shareholder assistants at the Annual General Meeting. Shareholders or its proxies may bring a maximum of two assistants, provided that their attendance is notified as above. Nominee-registered shares Proxy and proxy form Proxy form is available from the company and on the company’s website, www.vivesto.com, and is upon request sent to the shareholders who provide their postal address. Instructions for postal voting Shareholders who wish to submit its postal vote by proxy must issue a written and dated power of attorney signed by the shareholder for their proxy. If the power of attorney is issued by a legal person, a copy of the registration certificate or equivalent for the legal person must be attached. Shareholders may not provide special instructions or conditions to the postal vote. If so, the vote (i.e., the entire postal vote) is invalid. Further instructions and conditions can be found in the postal voting form. If a shareholder who has submitted a postal voting form attends the Annual General Meeting in person or by proxy, the postal vote lapses. Proposed agenda Proposed resolutions Item 2 – Election of Chairman of the Annual General Meeting Item 3 – Preparation and approval of the voting list Item 10 – Resolution on dispositions in respect of the company’s result pursuant to the adopted balance sheet Item 12 – Determination of the number of members and deputy members of the Board of Directors Item 13 – Determination of the number of auditors and deputy auditors Item 14 – Resolution on fees to the members of the Board of Directors • SEK 500,000 (500,000) to the Chairman of the Board and SEK 250,000 (250,000) to each of the other Board members elected by the Annual General Meeting who are not employed by the company, and • SEK 50,000 (50,000) to the Chairman of the Audit Committee and SEK 25,000 (25,000) to each of the other members of the Audit Committee, and SEK 50,000 (50,000) to the Chairman of the Remuneration Committee and SEK 25,000 (25,000) to each of the other members of the Remuneration Committee. Item 15 – Resolution on auditors’ fee Item 16 – Election of members of the Board of Directors and Chairman of the Board Information on all proposed members is available at the company’s website, www.vivesto.com. Item 17 – Election of auditor Item 18 – Resolution on approval of the remuneration report Item 19 – Resolution on guidelines for remuneration to senior executives These guidelines shall be applied to remuneration to the Chief Executive Officer, other members of Vivesto’s executive management and, where applicable, remuneration to directors of the Board of Directors in addition to directors’ fees. These guidelines replace the guidelines adopted by the Annual General Meeting 2020 and are applicable to remuneration agreed, and amendments to remuneration already agreed, after adoption of the guidelines by the Annual General Meeting 2024. The guidelines do not apply to remuneration decided by the general meeting. At the Annual General Meeting 2023, it was resolved to adopt an incentive programme for certain employees. For further information on the company’s current incentive programme, please see the company’s Annual Report. If a member of the Board of Directors should carry out services to Vivesto in addition to the Board assignment, these guidelines shall apply to any remuneration (for example consultancy fees) paid for such services. The Guidelines’ promotion of the company’s business strategy, long term interests and sustainability Types of remuneration Fixed remuneration Variable remuneration For the Chief Executive Officer, eventual variable remuneration during the same financial year may amount to not more than 50 percent of the fixed salary. For other members of Vivesto’s executive management the variable remuneration during one and the same financial year may amount to not more than 50 percent of the fixed remuneration. The fulfilment of criteria for payment of variable remuneration must be measurable during a period of one year. To which extent the criteria for awarding variable remuneration have been satisfied shall be evaluated when the measurement period has ended. The remuneration committee or, where applicable, the Board of Directors, is responsible for the evaluation. For financial objectives, the evaluation shall be based on the latest financial information made public by the company. Further, the Board of Directors has the right to reclaim variable remuneration that has been paid on the basis of information that later has turned out to be inaccurate and provided with a deceptive purpose. Pension Other benefits Extraordinary remuneration For employments governed by rules other than Swedish, the components of the total remuneration may be duly adjusted for compliance with mandatory rules or local practice, taking into account, to the extent possible, the overall purpose of these guidelines. Termination of employment For other people in the executive management, the period of notice shall be maximum six months regardless of whether the termination is initiated by the company or by the executive. No special severance pay shall be paid. Additionally, remuneration may be paid for non-compete undertakings. Such remuneration shall compensate for loss of income and shall only be payable in so far the previously employed executive is not entitled to severance pay. The remuneration may amount to not more than 60 percent of the fixed remuneration at the time of the termination and be payable during the time the non-compete undertaking applies, however not more than twelve months after the termination of the employment. Salary and employment conditions for employees Remuneration to directors of the Board of Directors The decision-making process to determine, review and implement the guidelines Deviation from the guidelines Description of significant changes in the remuneration guidelines and how comments brought forward by the shareholder has been assessed. The Board of Directors has not received any comments from shareholders regarding the remuneration guidelines adopted by the Annual General Meeting 2020. Item 20 – Resolution on authorization for the Board of Directors to resolve upon issues of shares, warrants and/or convertible instruments The purpose of the authorization and the reasons for any deviation from the shareholders’ preferential rights is to increase the company’s financial flexibility and the Board’s room for maneuver to raise capital in a time- and cost-effective manner and/or complement the shareholder base with new shareholders of strategic importance for the company, and enable the company to, fully or partially, finance any company acquisitions or acquisitions of businesses by issuing financial instruments as payment in connection with acquisitions, or to raise capital for such acquisitions. Issues made with deviation from the shareholders’ preferential rights shall take place at a subscription price in line with market conditions, including any discount in line with market conditions where applicable. If the Board of Directors deems it appropriate in order to enable the delivery of shares in connection with an issue as described above, the issue may be done at a subscription price equal to the quota value of the share. The Board of Directors, or the person appointed by the Board of Directors, shall have the right to make the minor adjustments to the above resolution that may prove necessary in connection with registration with the Swedish Companies Registration Office. Other information Majority requirements Number of shares and votes in the company Shareholders’ right to receive information Available documents Copies of the above documents are also sent to the shareholders who so request and provide their postal address. The documents will also be presented at the Annual General Meeting. Information on all proposed members of the Board of Directors, the Nomination Committee’s complete proposals and the Nomination Committee’s reasoned opinion regarding proposal for the Board of Directors is available on the company’s website, www.vivesto.com . Processing of personal data ____________ Stockholm in April 2024 |
||||
2024-04-23 | Vivesto | Kallelse till årsstämma i Vivesto AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-19 | Vivesto | Vivesto bjuder in till livesänd R&D Update med fokus på Paccal Vet den 26 mars | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-19 | Vivesto | Vivesto to hold live-streamed Paccal Vet R&D Update on March 26 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-07 | Vivesto | Vivesto doses first patient in its clinical Paccal Vet trial | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-03-07 | Vivesto | Första patienten doserad i Vivestos kliniska studie med Paccal Vet | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-02-26 | Penser Access by Carnegie | Penser Access by Carnegie: Intervju med Vivesto - Carnegie Investment Bank - 26 feb 2024 | Pressreleaser | Visa Stäng |
|
||||
2024-02-22 | Vivesto | Bokslutskommuniké för räkenskapsåret 1 januari – 31 december 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2024-01-30 | Vivesto | Vivesto's international patent application for XR-18 receives positive decision | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2024-01-30 | Vivesto | Vivestos internationella patentansökan för XR-18 får positivt besked | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-28 | Vivesto | Vivestos amerikanska kliniska studie med Paccal Vet får godkänt att starta patientrekrytering | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-28 | Vivesto | Vivesto’s US clinical Paccal Vet trial receives approval to start patient recruitment | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-22 | Vivesto | Vivestos Paccal Vet beviljas MUMS-klassificering av FDA | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-22 | Vivesto | Vivesto’s Paccal Vet granted FDA MUMS designation | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-22 | Vivesto | Vivesto gör nedskrivning av tillgångar efter tillbakadragande av de europeiska marknadsföringstillstånden för Apealea | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-22 | Vivesto | Vivesto makes impairment charge following withdrawal of European market authorizations for Apealea | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-19 | Vivesto | Vivesto reports positive preclinical data supporting continued development of Cantrixil | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-12-19 | Vivesto | Vivesto rapporterar positiva prekliniska data som stödjer fortsatt utveckling av Cantrixil | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-23 | Vivesto | Nomination Committee appointed for the 2024 Annual General Meeting in Vivesto | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-23 | Vivesto | Valberedning utsedd inför Vivestos årsstämma 2024 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-23 | Vivesto | Vivesto och Elevar tecknar avtal för att avsluta partnerskap rörande Apealea® | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-23 | Vivesto | Vivesto and Elevar sign agreement ending Apealea® partnership | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-11-17 | Penser Access | Penser Access: Intervju med Vivesto - Erik Penser Bank - 17 november 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-11-16 | Vivesto | Delårsrapport för perioden 1 januari – 30 september 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-11-16 | Vivesto | Interim report for the period January 1, 2023 – September 30, 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-10-26 | Penser Access | Penser Access: Intervju med Vivesto - Erik Penser Bank - 26 oktober 2023 | Pressreleaser | Visa Stäng |
|
||||
2023-10-25 | Vivesto | Vivesto focuses its project portfolio and introduces cost-saving measures | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-10-25 | Vivesto | Vivesto fokuserar projektportföljen och inför kostnadsbesparande åtgärder | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-15 | Vivesto | Delisting of Vivesto’s shares from Frankfurt Stock Exchange effective as of 15 September 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-09-15 | Vivesto | Avnotering av Vivestos aktier från Frankfurt Stock Exchange per den 15 september 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-24 | Vivesto | Delårsrapport för perioden 1 januari – 30 juni 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-24 | Vivesto | Interim report for the period January 1, 2023 – June 30, 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-08-04 | Vivesto | Vivesto meddelar att rekryteringen av patienter i den prövarinitierade fas 1b-studien med Docetaxel micellar avslutas i förtid | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-08-04 | Vivesto | Vivesto announces early termination of patient enrollment in the investigator-initiated Phase 1b Docetaxel micellar study | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-16 | Vivesto | Vivesto har haft positivt pre-submission möte med FDA om Paccal Vet | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-06-16 | Vivesto | Vivesto announces positive Paccal Vet FDA pre-submission meeting | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-25 | Vivesto | Kommuniké från årsstämma i Vivesto AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-25 | Vivesto | Report from Annual General Meeting in Vivesto AB | Pressreleaser | Ladda ner | Visa Stäng |
|
||||
2023-05-25 | Vivesto | Delårsrapport för perioden januari – mars 2023 | Rapporter | Ladda ner | Visa Stäng |
|
||||
2023-05-25 | Vivesto | Interim report for the period January 2023 – March 2023 | Rapporter | Ladda ner | Visa Stäng |
|